ArticleScientific reports2025
A blood-based co-expression signature of LncRNAs and transcription factors in neuromyelitis optica with diagnostic and mechanistic implications.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neuromyelitis optica (NMO) is an autoimmune disease that mainly affects the optic nerves and spinal cord. This disorder has been associated with dysregulation of several transcripts. We aimed to find possible peripheral markers for NMO through expression analysis of NF-κB-associated transcripts. Thus, we assessed expression of seven NF-κB-associated transcripts (including lncRNAs and mRNAs), namely ADINR, ANRIL, NKILA, PACER, DICER-AS, DILC, and CEBPA in the blood samples of NMO patients and healthy subjects. All seven transcripts demonstrated evidently higher expression in NMO patients compared with controls. The most prominent over-expression belonged to DICER-AS, followed by ADINR, PACER, NKILA, ANRIL, CEBPA, and DILC. All comparisons were statistically significant at P ≤ 0.0001, except DILC, which remained highly significant (P = 0.0001). Based on the ROC curve analyses, several transcripts, particularly, ADINR and DICER-AS could discriminate NMO patients from controls. The correlation in the expression of mentioned genes suggest a possible co-regulated lncRNA–transcription factor module in the blood of NMO patients that probably unites on NF-κB, IL-6/STAT3 and myeloid regulatory pathways. Taken together, these transcripts might be used in future biomarker discovery attempts for NMO in larger cohorts of NMO patients and controls.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.